The Supreme Court is set to weigh in on a significant legal battle that may impact the accessibility of the medication abortion drug mifepristone, particularly through mail services. Scheduled for oral arguments and with a ruling expected by June 30th, the case could have implications for the 2024 presidential election, as abortion remains a contentious issue among voters.
The Biden administration and pharmaceutical company Danco, the manufacturer of Mifeprex, are defending various FDA decisions that expanded the availability of the medication, including allowing mail delivery in 2021. White House Press Secretary Karine Jean-Pierre welcomed the Supreme Court’s scrutiny, arguing that a lower court ruling jeopardizes the FDA’s scientific autonomy.
With a conservative majority, the Supreme Court has signaled skepticism towards abortion rights in previous rulings, but the current case primarily addresses legal concerns related to the FDA’s drug approval process rather than directly challenging the right to abortion. The court will review FDA actions post-2016, including the 2021 decision allowing mail delivery, a reduction in in-person visits, and an extension of the usage window for mifepristone.
While the court rejected an appeal questioning the FDA’s initial 2000 approval of the drug, it will assess subsequent actions and their impact on patients, as asserted by the 5th U.S. Circuit Court of Appeals. The case originated from a lawsuit in November 2022 challenging the FDA’s decisions to expand access to mifepristone.
The Supreme Court’s decision in this case holds the potential to shape the future of medication abortion access, especially in the context of restrictive measures in several states, and may have political implications leading up to the 2024 election.
